|
|
 |
|
Viewing report
|
|
|
|
Mid Pharma Company Outlook to 2016
Datamonitor, Nov 2011, Pages: 38
This analysis examines the outlook for companies in the Mid Pharma peer set. The report encompasses insight into key strategic themes across the group of companies and identifies sales trends using 6-year prescription pharmaceutical sales forecasts for all the companies covered.
Features and benefits
- Gain insight into Mid Pharma companies strategic outlook across the next 6 years
- Analyze sales forecasts by company, therapy area, lifecycle stage, and molecule type.
Highlights
Strategic insight into the prospects for Mid Pharma companies over the next six years. Picking out key trends across the companies and comparing performance using a variety of cuts of forecast sales.
Your key questions answered
- Benchmark companies outlook against key rivals across the Mid Pharma peer set
- Assess how two companies in particular - Celegene and Gilead - will provide the majority of sales growth momentum within Mid Pharma through to 2016
|
|
|
|
